Literature DB >> 14871800

Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line.

Svetlana D Pack1, Ozgül M Alper, Kurt Stromberg, Meena Augustus, Metin Ozdemirli, Anne M Miermont, Greg Klus, Marek Rusin, Rebecca Slack, Neville F Hacker, Thomas Ried, Zoltan Szallasi, Ozge Alper.   

Abstract

Coexpression of epidermal growth factor receptor (EGFR) and c-erbB-2 in 47-68% of ovarian cancer cells indicate their strong association with tumor formation. We examined the effects of simultaneous antisense- or immunosuppression of EGFR and c-erbB-2 expression on the invasive phenotype, aneuploidy, and genotype of cultured human ovarian carcinoma cells (NIH:OVCAR-8). We report here that suppression of both EGFR and c-erbB-2 results in regression of aneuploidy and genomic imbalances in NIH:OVCAR-8 cells, restores a more normal phenotype, and results in a more normal gene expression profile. Combined with cytogenetic analysis, our data demonstrate that the regression of aneuploidy is due to the selective apoptosis of double antisense transfected cells with highly abnormal karyotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871800     DOI: 10.1158/0008-5472.can-03-1982

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.

Authors:  Agustin A Garcia; Michael W Sill; Heather A Lankes; Andrew K Godwin; Robert S Mannel; Deborah K Armstrong; Robert L Carolla; Marcia K Liepman; Nick M Spirtos; Edgar G Fischer; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2011-10-28       Impact factor: 5.482

Review 2.  EGFR/HER-targeted therapeutics in ovarian cancer.

Authors:  Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

3.  Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma.

Authors:  Heini Lassus; Harri Sihto; Arto Leminen; Heikki Joensuu; Jorma Isola; Nina N Nupponen; Ralf Butzow
Journal:  J Mol Med (Berl)       Date:  2006-04-11       Impact factor: 4.599

4.  A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.

Authors:  Edwin M Posadas; Meghan S Liel; Virginia Kwitkowski; Lori Minasian; Andrew K Godwin; Mahrukh M Hussain; Virginia Espina; Bradford J Wood; Seth M Steinberg; Elise C Kohn
Journal:  Cancer       Date:  2007-04-01       Impact factor: 6.860

Review 5.  Activated epidermal growth factor receptor in ovarian cancer.

Authors:  Laurie G Hudson; Reema Zeineldin; Melina Silberberg; M Sharon Stack
Journal:  Cancer Treat Res       Date:  2009

6.  Id-I stimulates cell proliferation through activation of EGFR in ovarian cancer cells.

Authors:  X Zhang; M-T Ling; H Feng; Y C Wong; S W Tsao; X Wang
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

7.  Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines.

Authors:  Natalia Vargas-Rondón; Erika Pérez-Mora; Victoria E Villegas; Milena Rondón-Lagos
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

8.  Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

Authors:  Doris R Siwak; Mark Carey; Bryan T Hennessy; Catherine T Nguyen; Mollianne J McGahren Murray; Laura Nolden; Gordon B Mills
Journal:  J Oncol       Date:  2009-11-19       Impact factor: 4.375

9.  Delineating the cytogenomic and epigenomic landscapes of glioma stem cell lines.

Authors:  Simona Baronchelli; Angela Bentivegna; Serena Redaelli; Gabriele Riva; Valentina Butta; Laura Paoletta; Giuseppe Isimbaldi; Monica Miozzo; Silvia Tabano; Antonio Daga; Daniela Marubbi; Monica Cattaneo; Ida Biunno; Leda Dalprà
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.